Clinical Trials

18 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05989828 2026-01-14

A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

Phase 1 Suspended

20 enrolled

Phase 1 Not yet recruiting

Triple Negative Breast Neoplasms

NCT07341867 2026-01-14

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

90 enrolled

BreastPlasma cell

Multiple Myeloma, Triple Negative Breast Neoplasms

NCT02208375 2025-12-31

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

159 enrolled

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT04427293 2025-12-16

Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)

Triple Negative Breast Neoplasms

NCT03542175 2025-12-08

A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy

31 enrolled 12 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02950259 2025-12-03

Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)

16 enrolled 10 charts

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT03109080 2025-11-24

RadioPARP

24 enrolled

Radiation Injuries, Triple Negative Breast Neoplasms

NCT07178171 2025-11-24

A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC

30 enrolled

Triple Negative Breast Neoplasms

NCT02826434 2025-10-01

Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer

22 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03362060 2025-10-01

PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer

20 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03945721 2025-09-29

UNITY

21 enrolled

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT04664829 2025-09-23

The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC

Triple Negative Breast Neoplasms

NCT06347068 2025-09-16

Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells

42 enrolled

Breast Neoplasms, Recurrence, Triple Negative Breast Neoplasms

NCT02792114 2025-07-17

T-Cell Therapy for Advanced Breast Cancer

186 enrolled

Phase 1 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06195618 2025-06-25

TEBICA003 TNBC

8 enrolled

Triple Negative Breast Neoplasms

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

BreastDermatologicGenitourinaryGynecologicThoracic

221 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT06246968 2025-05-21

A Study of Pembrolizumab and Cryoablation in People With Breast Cancer

30 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05868226 2025-04-04

PRE-I-SPY-PI

124 enrolled

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT05358639 2024-11-18

Combination of Olaparib and Navitoclax in Women with HGSC and TNBC

36 enrolled

BreastGynecologic

Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT03207529 2024-10-10

Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer

18 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02977468 2024-06-20

Pembro/IORT

15 enrolled

Triple Negative Breast Neoplasms

NCT03199040 2024-05-28

Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy

18 enrolled 9 charts

Triple Negative Breast Neoplasms

NCT02996825 2024-04-02

Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer

44 enrolled

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT04134884 2024-03-22

Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer

34 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03012230 2024-01-31

Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer

Triple Negative Breast Neoplasms

NCT05746897 2024-01-26

A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors

BreastDermatologicGastrointestinalGynecologic

38 enrolled

Melanoma, Ovarian Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT02672475 2023-11-22

Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer

29 enrolled

BreastGenitourinaryGynecologic

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04602117 2023-11-18

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

Phase 1 Withdrawn

Urinary Bladder Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04139993 2023-10-04

RBX7455 Before Surgery for the Treatment of Operable Breast Cancer

3 enrolled

Triple Negative Breast Neoplasms

NCT04081389 2023-09-11

Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer

9 enrolled 17 charts

Breast Carcinoma In Situ, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04185311 2023-08-15

Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted

6 enrolled

Breast Carcinoma In Situ, Triple Negative Breast Neoplasms

NCT01837602 2023-06-22

cMet CAR RNA T Cells Targeting Breast Cancer

6 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05774886 2023-05-18

Implantable Microdevice for TNBC - Pilot Study

Phase 1 Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01846091 2023-02-14

Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer

BreastHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05692661 2023-01-20

A Dose Escalation Study of Proton and Carbon Ion Irradiation for HER2 Positive and Triple Negative Breast Cancer

Phase 1 Unknown

24 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05093387 2022-11-15

SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer

Phase 1 Withdrawn

Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03579472 2022-10-31

M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer

38 enrolled

Triple Negative Breast Neoplasms

NCT01676753 2022-09-21

Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer

32 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02706392 2022-08-31

Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies

BreastLymphoidOther hematologic neoplasmThoracic

21 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung, Leukemia, Lymphocytic, Chronic, B-Cell, Hematologic Neoplasms, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Triple Negative Breast Neoplasms

NCT02719691 2022-07-25

Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer

47 enrolled 16 charts